Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome
mSystems · 22.10.2024 · 9 (10)
DOI: 10.1128/msystems.00788-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift mSystems, erschienen am 22.10.2024. Verfasst von Luyao Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Food Science and Engineering, Northwest A&F University, Shaanxi, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Systemic Inflammatory Response Syndrome, Fecal Microbiota Transplantation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China (NSFC), Key Research and Development Projects of Shaanxi Province, Foundation of State Key Laboratory of Component-Based Chinese Medicine.
Abstract (Originalsprache)
Systemic inflammatory response syndrome (SIRS) is a severe inflammatory response that can lead to organ dysfunction and death. Modulating the gut microbiome is a promising therapeutic approach for managing SIRS. This study assesses the therapeutic potential of the Xuanfei Baidu (XFBD) formula in treating SIRS. The results showed that XFBD administration effectively reduced mortality rates and inflammation in SIRS mice. Using 16S rRNA sequencing and fecal microbiota transplantation (FMT), we substantiated that the therapeutic effects of XFBD are partly attributed to gut microbiota modulation. We conducted in vitro experiments to accurately assess the gut microbiome remodeling effects of 51 compounds isolated from XFBD. These compounds exhibited varying abilities to induce a microbial structure that closely resembles that of the healthy control group. By quantifying their impact on microbial structure and clustering their regulatory patterns, we devised multiple gut microbiome remodeling compound (GMRC) cocktails. GMRC cocktail C, comprising aucubin, gentiopicroside, syringic acid, gallic acid, p-hydroxybenzaldehyde, para-hydroxybenzoic acid, and isoimperatorin, demonstrated superior efficacy in treating SIRS compared to a single compound or to other cocktails. Finally, in vitro experiments showcased that GMRC cocktail C effectively rebalanced bacteria composition in SIRS patients. This study underscores XFBD’s therapeutic potential in SIRS and highlights the importance of innovative treatment approaches for this disease by targeting the gut microbiota. IMPORTANCE Developing effective treatment strategies for systemic inflammatory response syndrome (SIRS) is crucial due to its severe and often life-threatening nature. While traditional treatments like dexamethasone have shown efficacy, they also come with significant side effects and limitations. This study makes significant strides by demonstrating that the Xuanfei Baidu (XFBD) formula can substantially reduce mortality rates and inflammation in SIRS mice through effective modulation of the gut microbiota. By quantitatively assessing the impact of 51 compounds derived from XFBD on the gut microbiome, we developed a potent gut microbiome remodeling compound cocktail. This cocktail outperformed individual compounds and other mixtures in efficacy against SIRS. These findings highlight the potential of XFBD as a therapeutic solution for SIRS and underscore the critical role of innovative strategies targeting the gut microbiota in addressing this severe inflammatory condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Food Science and Engineering, Northwest A&F University, Shaanxi, China.
- State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- Department of Emergency, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- College of Animal Science and Technology, Northwest A&F University, Shaanxi, China.
- Department of Critical Care Medicine, The Second Affiliated Hospital of Air Force Medical University, China, Shaanxi.
ORCID-Profile: Luyao Liu, Xin Zhao, Yanglei Yi
Förderung
- National Natural Science Foundation of China (NSFC)
- Key Research and Development Projects of Shaanxi Province
- Foundation of State Key Laboratory of Component-Based Chinese Medicine
Zitieren
APA
Liu, L., Ma, L., Liu, H., Zhao, F., Li, P., Zhang, J., Lü, X., Zhao, X., & Yi, Y. (2024). Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome. mSystems, 9(10). https://doi.org/10.1128/msystems.00788-24
Vancouver
Liu L, Ma L, Liu H, Zhao F, Li P, Zhang J, et al. Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome. mSystems. 2024;9(10). doi:10.1128/msystems.00788-24
BibTeX
@article{Liu2024,
author = {Liu, Luyao and Ma, Lin and Liu, Huan and Zhao, Fan and Li, Pu and Zhang, Junhua and Lü, Xin and Zhao, Xin and Yi, Yanglei},
title = {Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome},
journal = {mSystems},
year = {2024},
volume = {9},
number = {10},
doi = {10.1128/msystems.00788-24}
}
EUVIMED